您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
Siglec-15 mFc Chimera Protein, Human

Siglec-15 mFc Chimera Protein, Human

货号: UA010029
价格: 3000
规格: 100μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • Accession

    Q6ZMC9-1
  • 表达序列

    Phe20-Thr263, with C-terminal Mouse Fc
  • 表达宿主

    HEK293
  • 分子量

    60-65 kDa(Reducing)
  • 纯度

    >95%, by SDS-PAGE under reducing conditions
  • 内毒素含量

    <0.1EU/μg
  • 标记

    Unconjugated
  • 标签

    Mouse Fc Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4
  • 溶解方法

    Reconstitute at less than 1 mg/mL according to the size in ultrapure water after rapid centrifugation .
  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.
  • 稀释度

背景介绍
  • Siglec-15, one of the Sialic acid-binding immunoglobulin-like lectins (Siglecs) and type-1 transmembrane protein, is expressed mainly in human macrophages and dendritic cells. It is comprised of a lysine-containing transmembrane domain, two extracellular immunoglobulin (Ig)-like domains and a short cytoplasmic domain. Siglec-15 is highly conserved in vertebrates and acts as an immunoreceptor. It exerts diverse functions on osteoclast physiology as well as the tumor microenvironment. Unlike most Siglecs, which are inhibitory receptors, it associates with adapter proteins DAP10 and DAP12 via a transmembrane Lys274 residue for signal activation. Siglec-15 interacts with adapter protein DAP12-Syk signaling pathway to regulate the RANKL/RANK-mediated PI3K, AKT, and ERK signaling pathways during osteoclast formation in vitro. More recently, high Siglec-15 was also found to promote osteosarcoma progression via the activation of the DUSP1/MAPK signaling pathway, and hepatocellular carcinoma migration via CD44 interaction, which prevented lysosomal degradation. As Siglec-15 is mutually exclusive to PD-L1, it is now emerging as a novel immune inhibitor for anti-PD-1/PD-L1 resistant patients.